As on Wednesday, Neogenomics Inc (NASDAQ: NEO) got off with the flyer as it spiked 3.26% to $17.74, before settling in for the price of $17.18 at the close. Taking a more long-term approach, NEO posted a 52-week range of $12.77-$21.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 17.35%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 180.95%. This publicly-traded company’s shares outstanding now amounts to $127.37 million, simultaneously with a float of $126.80 million. The organization now has a market capitalization sitting at $2.28 billion. At the time of writing, stock’s 50-day Moving Average stood at $14.69, while the 200-day Moving Average is $14.93.
Neogenomics Inc (NEO) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Diagnostics & Research industry. Neogenomics Inc’s current insider ownership accounts for 1.22%, in contrast to 97.47% institutional ownership. According to the most recent insider trade that took place on Nov 15 ’24, this organization’s General Counsel sold 5,175 shares at the rate of 15.36, making the entire transaction reach 79,475 in total value, affecting insider ownership by 37,129.
Neogenomics Inc (NEO) Earnings and Revenue Records
Neogenomics Inc’s EPS increase for this current 12-month fiscal period is 180.95% and is forecasted to reach 0.20 in the upcoming year.
Neogenomics Inc (NASDAQ: NEO) Trading Performance Indicators
Let’s observe the current performance indicators for Neogenomics Inc (NEO). It’s Quick Ratio in the last reported quarter now stands at 1.91. The Stock has managed to achieve an average true range (ATR) of 0.63. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.54.
In the same vein, NEO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.62, a figure that is expected to reach 0.03 in the next quarter, and analysts are predicting that it will be 0.20 at the market close of one year from today.
Technical Analysis of Neogenomics Inc (NEO)
Through scrutinizing the latest numbers posted by the [Neogenomics Inc, NEO], it can be observed that its last 5-days Average volume of 0.62 million was lower the volume of 0.81 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 95.77% While, its Average True Range was 0.65.
Raw Stochastic average of Neogenomics Inc (NEO) in the period of the previous 100 days is set at 90.20%, which indicates a major fall in contrast to 98.65% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 44.52% that was lower than 51.03% volatility it exhibited in the past 100-days period.
